Skip to content

Egg oral immunotherapy with probiotics for severe egg allergy

Probiotics combined with oral Immunotherapy for patients with severe egg allergy: A multicenter, randomized, double-blind, placebo-controlled clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs041220087
Enrollment
80
Registered
2022-11-01
Start date
2023-01-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

food allergy Food Hypersensitivity

Interventions

This study is a double-blind, placebo-controlled, randomized, controlled trial.The study drug (probiotics or placebo) is 1 g once daily for 1 year. The study drug for probiotics contains 0.03 g of LGG

Sponsors

Nagakura Ken-Ichi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Patients between 5 and 18 years of age (2) Patients whose obvious immediate-type allergic symptoms were induced by less than 1/8 of a heated whole egg (775 mg of egg protein) in oral food challenge (3) Patients whose consent to participate in this study has been obtained

Exclusion criteria

Exclusion criteria: (1)Patients with poorly controlled bronchial asthma(C-ACT or ACT 19 points or lower) (2)Patients with poorly controlled atopic dermatitis(EASI 16 points or higher) (3)Patients receiving other immunotherapies at the study entry. However, patients who have been on Japanese cedar or house dust mite SLIT or SCIT for at least 1 year and are stable without adverse reactions may be treated at the discretion of the attending physician. (4) Patients on biological agents at the study entry. (5) Patients using systemic steroids or immunosup pressive drugs at the study entry. (6) Patients with diseases affecting the immune system (autoimmune diseases, immune complex diseases, immunodeficiency diseases, etc.) (7) Patients using antibiotics within 1 month of study entry (8) Patients whose physician determines that it is difficult to perform the study

Design outcomes

Primary

MeasureTime frame
Percentage of the patients who acquired tolerance for 1/2 a heated whole egg after 12 months from start of oral immunotherapy.

Secondary

MeasureTime frame
Percentage of the patients who acquired desensitization to 1/8 of a heated whole egg after 12 months from start of oral immunotherapy. Frequency of adverse reactions during 12 months. Rates of changing egg white/ovomucoid-specific IgE, IgG, and IgG4 levels during 12 months. Number of infections with fever or requiring hospitalization during 12 months. Diversity of the intestinal microbiota and change in bacterial species by 16S rRNA analysis. Rates of changing in serum short-chain fatty acids during 12 months.

Contacts

Public ContactKen-Ichi Nagakura

National Hospital Organization Sagamihara Nation al Hospital

k.nagakura@foodallergy.jp+81-42-742-8311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026